![Thierry Nivaggioli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thierry Nivaggioli
Keine laufenden Positionen mehr
Profil
Thierry Nivaggioli worked as a Development Director at Ortho-McNeil Pharmaceutical LLC, Director-Research & Formulation Development at Oculex Pharmaceuticals, Inc., and Vice President-Research & Development at MacuSight, Inc. He holds a doctorate degree from the University of Toronto, a graduate degree from Université de Bordeaux, and an undergraduate degree from Université Paris 1 Panthéon-Sorbonne.
Ehemalige bekannte Positionen von Thierry Nivaggioli
Unternehmen | Position | Ende |
---|---|---|
Oculex Pharmaceuticals, Inc.
![]() Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ortho-McNeil Pharmaceutical LLC
![]() Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ. | Corporate Officer/Principal | - |
MacuSight, Inc.
![]() MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Thierry Nivaggioli
University of Toronto | Doctorate Degree |
Université de Bordeaux | Graduate Degree |
Université Paris 1 Panthéon-Sorbonne | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
MacuSight, Inc.
![]() MacuSight, Inc. Pharmaceuticals: MajorHealth Technology MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA. | Health Technology |
Oculex Pharmaceuticals, Inc.
![]() Oculex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oculex Pharmaceuticals, Inc. manufactures and develops drugs. The company focuses on developing and manufacturing novel drug delivery systems that resolve the problems associated with treatment of inflammation following cataract surgery and diseases of the eye. It is located in Sunnyvale, CA. | Health Technology |
Ortho-McNeil Pharmaceutical LLC
![]() Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ. | Health Technology |